At the recent European Society of Cardiology (ESC) Symposium, promising interim results were presented from an ongoing study on Catheter Precision, Inc.’s VIVO technology, a non-invasive tool for localizing the origin of ventricular tachycardia (VT) in patients with scar-related re-entrant VT. The study, led by Professor Tarv Dhanjal at Warwick Medical School, is being conducted at University Hospitals of Coventry and Warwickshire.
The presentation, titled “Accuracy of a non-invasive mapping system for the localization of re-entrant VT site of origin and its relationship to myocardial scar on cross-sectional imaging,” highlighted the accuracy of VIVO in comparison to traditional invasive mapping techniques. Among the 20 patients studied, all of whom suffered from structural heart disease with an average ejection fraction of 35.5%, VIVO demonstrated 90% accuracy when matched against invasive mapping performed with the Abbott Advisor HD Grid multipolar catheter. The results were particularly significant in relation to myocardial scarring, a common complication in these patients.
The ongoing study encompasses patients with various forms of heart disease, including ischemic cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy. With a mean follow-up period of seven months, procedural success has been achieved in 90% of the patients.
David Jenkins, CEO of Catheter Precision, emphasized the importance of the findings, stating, “These are significant results in very sick patients with scarred heart muscle and structural heart disease. We are excited about the prospect of enrolling additional patients and further validating VIVO’s potential in treating this group of patients in need of advanced medical care.”
VIVO, a non-invasive 3D imaging system developed by Catheter Precision, is designed to help physicians identify the origin of ventricular arrhythmias before performing procedures. By providing a pre-procedure mapping tool, VIVO aims to streamline workflow and reduce overall procedure time. It has received clearance from the U.S. FDA and holds the CE Mark for its use in Europe.